Effect of stavudine-based antiretroviral therapy on the severity of polyneuropathy in HIV/AIDS patients: A preliminary report from Zaria, Northern Nigeria;Effet de la stavudine-traitement antirétroviral à base de la gravité de Polynévrite au cours de lutte contre le VIH / SIDA patients: Un rapport préliminaire de Zaria, au Nigeria du Nord

West African Journal of Medicine

Volumn 30, Issue 5, 2011, Pages 354-358

  Obiako, O R ^a   Abdu Aguye, I ^a   Ogunniyi, A ^b  

^a AHMADU BELLO UNIVERSITY   (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Antiretroviral therapy; Distal symmetrical polyneuropathy; HIV AIDS; Nucleoside reverse transcriptase inhibitors; Stavudine

Indexed keywords

LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; NIGERIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; QUESTIONNAIRE; RISK FACTOR; TREATMENT DURATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NIGERIA; POLYNEUROPATHIES; RETROSPECTIVE STUDIES; RISK FACTORS; STAVUDINE; YOUNG ADULT;

EID: 84862001603     PISSN: 0189160X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Isezuo SA, Sani AZ, Ezunu E, Maiyaki S, Njoku CH, Obembe A. Clinical neuropathy in HIV/AIDS: an eight-year review of hospitalized patients in Sokoto, northwestern Nigeria. Tropical Doctor 2009; 39: 133-13.
2. Ogun SA, Ojini F, Okubadejo N, Danesi M, Kolapo K, Osalusi B, et al. Pattern and outcome of neurological manifestations of HIV/AIDS-A review of 154 cases in a Nigerian Univ. Teaching Hosp. A preliminary report. Afr J Neurol Sciences 2005; 24: 1-11.
3. Polydefkis M J. Peripheral Neuropathy and HIV: The Hopkins HIV Report, 2002; 14: 6-7.
4. Schiffitto G, McDermott M, McArthur JC. Incidence of and risk factors for HIV-associated distal symmetrically polyneuropathy. Neurology 2002; 58: 1764-8.
5. Simpson D. Selected peripheral neuropathies associated with HIV-1 infection and antiretroviral therapy. J Neurovirology 2002; 8: 33-41.
6. Cepeda J A, Wilks D. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV treatment. AIDS 2000; 14: 332-3.
7. Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: Insights in the pathology of HIV peripheral nerve disease. J Peripheral Nerv System 2001; 6: 21-27.
8. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
9. Famularo G, Moretti S, Marcellini S. Acetyle-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997; 11: 185-90.
10. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N. British HIV Association (BHIVA) guidelines for the treatment of HIVinfected adults with antiretroviral therapy. HIV Medicine 2006; 7: 487-503.
11. United States Department of Health and Human Services (DHHS): Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, 2006. Available from http://www. aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
12. World Health Organisation: Antiretroviral therapy for HIV infection in adults and adolescents in resourcelimited settings: Towards universal access. Recommendations for a public health approach. World Health Organisation, Geneva, Switzerland 2006.
13. Margaret O. Araoye. Sample Size Determination. In: Research Methodology with Statistics for Health and Social Sciences. 2004 Edition. Nathadex Publishers, Ilorin. Pg. 115-120.
14. Federal Ministry of Health, Dept of Public Health, National AIDS/STI Control Programme. National HIV/ Syphilis Sero-prevalence Sentinel Survey Technical Report, 2005
15. McArthur JH. The reliability and validity of the subjective peripheral neuropathy screen. J Assoc Nurses in AIDS Care 1998; 9: 84.
16. Bennett M. The S-LANNS Score for identifying pain of predominantly neuropathic origin: Validation for use in clinical and postal research. The Journal of Pain 2005; 6: 149-158.
17. Chesney M A, Ickovics J R, Chambers D B, Gifford A L, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care 2000; 12: 255-266.
18. Marlink R, Kanki P, Thior I. Reduced rate of disease development with HIV-2 compared to HIV-1. Science, 1994; 265: 1587-1590.
19. Simpson D M, Haidich A B, Schiffito G. Severity of HIV-associated neuropathy is associated with plasma HIV-RNA levels. AIDS 2002; 16: 407-412.
20. Martin C, Solders G, Sonnerbory A. Antiretroviral therapy may improve sensory function in HIV-infected patients: A pilot study. Neurology 2000; 54: 2120-2127.
21. Potchoo Y, Tchamdja K, Balogou A, Pitche VP, Guissou IP, Kassang EK. Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the Health Care Centers of the Association " Espoir Vie Togo", West Africa. BMC Clin Pharmacol. 2010; 10: 1-7.
22. Laurent C, Bourgeois A, Mpoudi-Ngole E, Ciaffi L, Kouanfack C, Mougnutou R, et al. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS Research and Human Retroviruses 2008; 24: 393-399.
23. Forna F, Liechty C A, Solberg P. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007; 44: 456-462.
24. Colbunders R. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: Good virological response but high rate of toxicity. J International Assoc. Physicians in AIDS Care 2009; 8: 52-59.
25. Justesen U S. Adverse PI drug-drug interactions and toxicity. In: Protease inhibitors plasma concentrations in HIV antiretroviral therapy. Doctor of Medical Science Thesis. Danish Medical Bulletin 2008; 55: 172-177.